Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 18/20 | 0.44 |
| ▸ | MMP9 | P14780 | 12/20 | 0.44 |
| ▸ | MMP13 | P45452 | 12/20 | 0.44 |
| ▸ | MMP1 | P03956 | 11/20 | 0.44 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657755 | 0.85 | ADAM17 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5659505 | 0.83 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5659508 | 0.83 | ADAM17 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6409762 | 0.83 | ADAM17 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6275169 | 0.83 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6414957 | 0.81 | ADAM17 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5657792 | 0.81 | ADAM17 (0.63) | ADAM17MMP9MMP13MMP1MMP2 | |
| SCHEMBL10532742 | 0.77 | EPHX2 (0.46) | — | |
| SCHEMBL10578255 | 0.75 | ADAM17 (0.46) | ADAM17MMP9MMP13MMP1ADAM10 | |
| SCHEMBL10572381 | 0.73 | CA12 (0.44) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272928-A1 | Method for preparing hydroxamic acids | WYETH (US) | 2005-12-08 | — | — | US | claimed |
| EP-1534707-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO (3, 4-B) -QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-01 | — | — | EP | claimed |
| EP-1296981-B1 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2004-10-06 | — | — | EP | claimed |
| US-6800625-B2 | FOR THERAPY OF SEXUAL DYSFUNCTION | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-05 | — | — | US | claimed |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2004-03-04 | — | — | US | claimed |
| US-20040006079-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO[3,4-B]QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | JENSEN PHARMACEUTICAL N.V. (BE) | 2004-01-08 | — | — | US | claimed |
| WO-2004000842-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO (3, 4-B) -QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-31 | — | — | WO | claimed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | claimed |
| EP-1296981-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-04-02 | — | — | EP | claimed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | claimed |
| WO-2001087882-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | claimed |
| EP-1534707-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO (3, 4-B) -QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| US-6818646-B2 | 1,2,3,4-TETRAHYDRO-2-(5-(2-PYRIDINYL)-PYRIMIDIN-2-YL)-3-(2,3 -DIHYDROBENZOFURANYL)-9H-PYRROLO-(3,4-B)QUINOLIN-9-ONE; MALE ERECTILE DYSFUNCTION; SEXUAL DISORDERS | SUI ZHIHUA (US) | 2004-11-16 | — | — | US | disclosed |
| EP-1296981-B1 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004000842-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO (3, 4-B) -QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-31 | — | — | WO | disclosed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1296981-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001087882-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | CA12 4745/4885CA1 4431/4885CA2 3080/4885 |
| US-20040006079-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO[3,4-B]QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE3B, PDE5A | CA12 4565/4885CA1 3957/4885CA2 1751/4885 |
| US-20050272928-A1 | Method for preparing hydroxamic acids | H1-5, HDAC5, PGA5 | CA12 168/4885CA1 23/4885CA2 205/4885 |
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | CA12 4708/4885CA1 4336/4885CA2 3052/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | CA12 4708/4885CA1 4336/4885CA2 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.